Studies of the Efficacy of Cereton in Mild Cognitive Impairment of the Amnestic Type Based on Testing Lipid Markers
- 2 Downloads
Objectives. To determine the efficacy and safety of treatment with Cereton (alfoscerate) in patients with mild cognitive impairment syndrome (MCI) and its effects during and after treatment on phosphatidyl-choline, sphingomyelin, and ceramide (a sphingolipids metabolite) contents and the activity of genes controlling the synthesis of enzymes (sphingomyelinase and ceramidase) involved in the sphingomyelin and ceramide metabolism. Materials and methods. A total of 20 patients (14 women, six men) aged 51–82 (mean 70.3 ± 9.1) years were studied. Patients’ status corresponded to the criteria for diagnosis of MCI syndrome of the anamnestic type. Plasma phosphatidylcholine, sphingomyelin, and ceramide were estimated by thin layer chromatography, while expression of the sphingomyelinase and ceramidase genes was determined using the reverse transcriptase polymerase chain reaction. Results and conclusions. Sharp increases in the contents of phosphatidylcholine and ceramide – hydrolysis products of sphingomyelin – were seen. Expression of the genes (acid sphingomyelinase and ceramidase) controlling ceramide metabolism decreased in most patients during Cereton treatment. Increases in the levels of phosphatidylcholine and decreases in the expression of ceramide metabolism genes during treatment with Cereton and other agents affecting phosphatidylcholine and sphingomyelin metabolism can be used as markers for treatment efficacy.
Keywordsmild cognitive impairment (MCI) phosphatidylcholine sphingomyelin ceramide sphingomyelinase ceramidase
Unable to display preview. Download preview PDF.
- 1.S. I. Gavrilova (ed.), Handbook for Geriatric Psychiatry, Pulse, Moscow (2001).Google Scholar
- 2.Ya. B. Kalyn and S. I. Gavrilova, “Dynamics of measures of the prevalence of mental disorders in the elderly and old population,” in: Reforms in Mental Health Services: Challenges and Perspectives (1997), pp. 181–189.Google Scholar
- 3.N. D. Selezneva, N. M. Mikhailova, Ya. B. Kalyn, I. F. Roshchina, and S. I. Gavrilova, “Studies of the efficacy and safety of Actovegin in elderly patients with mild cognitive impairment syndrome of cerebrovascular origin,” Psikhiatriya, 1, 37–50 (2009).Google Scholar
- 4.S. I. Gavrilova, I. V. Kolykhalov, Ya. B. Fedorova, et al., “Potentials for preventive treatment in Alzheimer’s disease: results of a three-year prospective, open, comparative trial of the efficacy and safety of courses of treatment with Cerebrolysin and Cavinton in elderly patients with mild cognitive impairment syndrome,” Zh. Nevrol. Psikhiat., 1, 68–75 (2010).Google Scholar
- 7.A. V. Alessenko and S. V. Gurianova, “Potential role of ceramides in neurodegenerative diseases,” in: Sphingomyelin and Ceramides: Occurrence, Biosynthesis and Role in Disease, NOVA Science Publisher, New York (2015), pp. 21–53.Google Scholar
- 8.T. A. Ban, R. M. Panzarasa, S. Borra, D. Del Duchetto, and O. K. Fjetland, “Choline alphoscerate in elderly patients with cognitive decline due to dementing illness,” New Trends Clin. Neuropharmacol., 5, 1–35 (1991).Google Scholar
- 9.O. A. Shavlovskaya, “Experience in the use of Cereton (choline alfoscerate) in clinical practice,” Rus. Med. Zh., 19, No. 9, 557–561 (2011).Google Scholar
- 11.E. Aguglia, T. A. Ban, R. M. Panzarasa, S. Borra, and O. K. Fietland, “Choline alphoscerate in the treatment of mental pathology following acute cerebrovascular accident,” Funct. Neurol., 8, Suppl. 3, 5–24 (1993).Google Scholar
- 13.T. V. Builova, M. E. Glotova, M. E. Khalak, and V. V. Vashkevich, “Experience in the use of Cereton in the process of rehabilitation of patients with hemorrhagic stroke,” Zh. Nevrol. Psikhiat., 5, No. 2, 58–62 (2009).Google Scholar
- 14.S. I. Gavrilova, A. V. Alesenko, I. V. Kolykhalov, et al., “Clinical-biological effects of Cereton in the treatment of mild cognitive impairment syndrome of the amnestic type,” Psikhiatriya, 73, No. 1, 5–15 (2017).Google Scholar
- 19.N. Bartke and Y. A. Hannun, “Bioactive sphingolipids: metabolism and functions,” J. Lipid Res., 50, supplement, 91–96 (2009), https://doi.org/10.1194/jlr.R800080-JLR200.
- 22.P. Katsel, C. Li, and V. Haroutunian, “Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer’s disease: A shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer’s disease?” Neurochem. Res., 32, 845–856 (2007), https://doi.org/10.1007/s11064-007-9297-x.CrossRefPubMedGoogle Scholar